Clinical trials: Breast Cancer, Breast Neoplasms
Breast Cancer, Medication Adherence
SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors
The purpose of this study is to determine whether weekly SMS reminders are effective in improving medication adherence of adjuvant aromatase inhibitors in women with breast cancer.
- Trial name
- NCT02524548
- Testing
- SMS reminder
- Where
- 2 sites in Singapore
- Volunteers
- 244 people
- Sponsor
- National University of Singapore
Breast Cancer
Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer
RATIONALE: Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of abiraterone acetate and to see…
- Trial name
- NCT00755885
- Testing
- abiraterone acetate, laboratory biomarker analysis, pharmacogenomic studies
- Where
- 6 sites in United Kingdom
- Volunteers
- 77 people
- Sponsor
- Cancer Research UK
Breast Cancer
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
Prospective, multi-center, randomized, open label comparative Phase III study in patients with intermediate to high-risk (as defined in the SURVIVE trial) HER2-positive or HER2-low early breast cancer, who participate in the…
- Trial name
- SURVIVE HERoes (NCT06643585)
- Testing
- Trastuzumab-Deruxtecan, Physicians Choice (PhC).
- Where
- Germany
- Volunteers
- 180 people
- Sponsor
- Prof. Wolfgang Janni
Breast Cancer
Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)
The purpose of this research is to establish if a once a year dose of Zoledronic Acid is sufficient to suppress and maintain urine and serum bone density markers (NTx) and serum CTx within normal range at 12 months post-dosing in…
- Trial name
- CTIBL (NCT00712985)
- Testing
- Zometa
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer
A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
This open-label, randomized crossover study evaluated the quality of life, efficacy, and safety of subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper arm of participants with early HER2-positive…
- Trial name
- LISAH (NCT01928615)
- Testing
- Trastuzumab - intravenous solution, Trastuzumab - subcutaneous solution, Chemotherapy
- Where
- 2 sites in Austria
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Advanced or Metastatic ER+ Breast Cancer
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with…
- Trial name
- NCT02734615
- Testing
- LSZ102, LEE011, BYL719
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Mammary Cancer
Open Technique Interpectoral Catheter for Postoperative Analgesia in Modified Radical Mastectomy
patients undergoing modified radical mastectomy were divided into two groups. patients in catheter group were placed a catheter with open technique by the surgeon in the pectoral area.
- Trial name
- NCT03204708
- Testing
- catheter, iv analgesia
- Volunteers
- 86 people
- Sponsor
- Istanbul University
Breast Neoplasms
Multimodal Respiratory Physiotherapy in Women Receiving Radiotherapy for Breast Cancer (RESPIRA-BC)
Radiotherapy is an important treatment for breast cancer, but it may affect lung function and physical ability, making everyday activities more difficult.
- Trial name
- RESPIRA-BC (NCT07884968)
- Testing
- Incentive Spirometry (IS) and Positive Expiratory Pressure (PEP) Training, Individualised Exercise Programme (Aerobic and Resistance Training), Patient Education Programme
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- University of Alcala
Breast Cancer
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT01160718
- Testing
- fulvestrant, selumetinib
- Where
- 17 sites in Belgium, Switzerland
- Volunteers
- 46 people
- Sponsor
- Swiss Cancer Institute
Contour Irregularity of Reconstructed Breast
Tissue Expander Breast Reconstruction Study on Breast Volume and Shape Change
The purpose of this study is to explore the volume change and location of volume change in reconstructed breasts using the Contour Profile® tissue expander.
- Trial name
- CPX3 (NCT01222390)
- Testing
- Contour Profile Tissue Expander
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Ovarian Cancer, Breast Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs.
- Trial name
- NCT01623349
- Testing
- BKM120 and Olaparib, BYL719 and Olaparib
- Where
- 5 sites in United States
- Volunteers
- 118 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Neoplasms Diagnosis, Brest Cancer
Wide-Angle Tomosynthesis and AI in Diagnostic Mammography
Breast cancer remains the most commonly diagnosed cancer and a leading cause of cancer-related mortality among women globally. Timely and accurate detection is crucial for improving prognosis and survival outcomes.
- Trial name
- NCT07491055
- Volunteers
- 1,400 people
- Sponsor
- Jean Seely
Breast Cancer
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer
Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose…
- Trial name
- Subito (NCT02810743)
- Testing
- ddAC-CP-Olaparib, ddAC-mini CTC
- Where
- 11 sites in France, Netherlands
- Volunteers
- 174 people
- Sponsor
- The Netherlands Cancer Institute
Breast Neoplasms
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.
- Trial name
- NCT00034125
- Testing
- LY353381, tamoxifen
- Where
- 11 sites in United States, Argentina and 3 more
- Sponsor
- Eli Lilly and Company
Breast Cancer
Effect of Midazolam Premedication Before Induction on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Surgery Due to Breast Cancer
Normally, higher levels of preoperational stress or anxiety affect behavior and recovery after the operation. Moreover, patients undergoing mastectomy are usually young women, and this demographic is known to experience higher…
- Trial name
- NCT01945476
- Testing
- midazolam premedication
- Where
- South Korea
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Breast Cancer Female, Surgery
An Innovative Care-improvement Smartphone-based Perioperative Solution for Women Undergoing Breast Cancer Surgery
This study aims to develop a mobile app-based periopeartive intervnetion for women undergoing breast cancer surgery and examine the effectiveness of the program on participants' health outcomes of self-efficacy, anxiety and…
- Trial name
- iCareBreast (NCT04172350)
- Testing
- iCareBreast, Routine care
- Where
- Singapore
- Volunteers
- 112 people
- Sponsor
- HE Hong-Gu
Locally Advanced or Metastatic Breast Cancer
A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
This study aims to evaluate the efficacy of Entinostat combined with Fulvestrant in HR+/HER2- advanced breast cancer patients with recurrence/progression after endocrine therapy (primary endpoint: progression-free survival…
- Trial name
- NCT07235618
- Testing
- Entinostat, Fulvestrant
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Lymphedema
Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Patients Who Have Undergone Radiation Therapy for Cancer
RATIONALE: Hyperbaric oxygen therapy may be effective in repairing damaged tissue and reducing lymphedema caused by radiation therapy for cancer.
- Conditions
- Breast Cancer, Lymphedema, Perioperative/Postoperative Complications, Radiation Fibrosis
- Trial name
- NCT00077090
- Testing
- hyperbaric oxygen
- Where
- 5 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
Postoperative Identification of Tumor Cells At the Lumpectomy Site of Patients with Early Breast Cancer
For early breast cancer, local surgery followed by breast radiation is a standard local treatment. It has been found that the original primary tumor site, the lumpectomy site, is the commonest location of local relapse.
- Trial name
- NCT04339517
- Testing
- Aspiration of seroma fluid
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
This is a a phase III, randomized, open-label clinical trial comparing endocrine therapy combined with high-dose palbociclib and hydroxychloroquine to endocrine therapy combined with standard-dose palbociclib for hormone…
- Trial name
- NCT07061717
- Testing
- Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd, Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid, Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.